AcquisitionOther
Solid Biosciences Inc. acquired AavantiBio, a privately held gene therapy company focused on transforming the lives of patients
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Solid Biosciences Inc. -> AavantiBio, a privately held gene therapy company focused on transforming the lives of patients · $75 million
The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreichs ata
Open source record (SEC) ↗